Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sina Salem Ahim has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Antiphospholipid antibody nephropathy in pregnancy; consequences for fetal renal development and maternal health outcomes

    by Maryam Kazemi, Arezoo Harsjian, Azam Moridi, Sadaf Rassouli, Zahra Hamidi Madani, Zeinab Zamanpour, Forouhar Darabi, Roya Biglarifar, Zohreh Sanjarian, Zahra Kamranirad, et al.

    Antiphospholipid antibody (aPL) nephropathy in pregnancy is a critical and complex medical condition that poses significant risks to both maternal renal health and fetal development. This autoimmune disorder is characterized by the presence of aPLs, which target phospholipid-binding proteins, leading to a procoagulant state. In the context of pregnancy, this predisposition to thrombosis can manifest as thrombotic microangiopathy (TMA) within the renal vasculature, directly impacting kidney function. The resulting renal microvascular injury contributes to a decline in maternal renal health, potentially leading to proteinuria, hypertension, and even acute kidney injury, exacerbating the already delicate physiological changes of pregnancy. The intricate interplay between autoimmune-mediated thrombosis and placental dysfunction is central to the high-risk nature of this condition. aPLs can cause thrombosis in the placental vasculature, leading to placental insufficiency, intrauterine growth restriction, preeclampsia, and recurrent pregnancy loss. This compromise in placental blood flow not only jeopardizes fetal development but also indirectly strains maternal renal function. The systemic inflammation and endothelial dysfunction associated with aPLs further complicate the clinical picture, making accurate diagnosis and timely intervention paramount for managing these multifaceted challenges. Effective management of aPL nephropathy in pregnancy necessitates a highly individualized and multidisciplinary approach, focusing on meticulous monitoring of both maternal and fetal well-being. This includes close surveillance of renal function, blood pressure, and proteinuria, alongside regular assessments of fetal growth and placental health. Therapeutic strategies often involve anticoagulation with heparin, sometimes combined with low-dose aspirin, to mitigate the thrombotic risk. Such precise monitoring and tailored interventions are crucial for optimizing outcomes, aiming to preserve maternal renal health while supporting successful fetal development in this challenging clinical scenario.

  • Open Access

    Non-coding RNAs in neurodegeneration: an axis-based, evidence-tiered mechanistic synthesis

    by Sina Salem Ahim, Mehrdad Bandegi, Erfan Ghanbarzadeh, Roozbeh Heidarzadehpilehrood


  • Renal manifestations and implications in polycystic ovary syndrome; an analytical review

    by Sina Salem Ahim, A. Mokhtariardekani, H. Sanadgol, S. Hosseinian, M. SalekShahabi, A. Emadzadeh, Z. Sanjarian, A. Abbasszade, Z. Hamidi Madani

    Insulin resistance in polycystic ovary syndrome (PCOS) contributes to renal dysfunction through multiple interconnected mechanisms. In PCOS, insulin resistance leads to compensatory hyperinsulinemia, which exacerbates metabolic disturbances including hyperandrogenism and systemic inflammation. These factors collectively promote renal injury. Meanwhile, insulin resistance in PCOS promotes hypertension and endothelial dysfunction, which impair renal microcirculation. Hyperinsulinemia increases sodium retention and activates the renin-angiotensin-aldosterone system (RAAS), further elevating blood pressure and causing glomerular hyperfiltration and damage. Insulin resistance also contributes to dyslipidemia and oxidative stress, accelerating atherosclerosis and renal vascular injury. Moreover, insulin resistance worsens hyperuricemia by reducing renal uric acid excretion, which is a direct nephrotoxic factor. Persistent hyperuricemia leads to inflammation and fibrosis within the kidneys, potentially progressing to chronic kidney disease (CKD). In addition, systemic low-grade inflammation and oxidative stress driven by insulin resistance and PCOS-related hyperandrogenism also induce renal tissue injury through inflammatory cytokines and apoptotic pathways, contributing to impairment in renal function.

  • Open Access

    Role of uterine artery Doppler sonography in prediction and management of preeclampsia: a systematic review analysis of the recent 10-year evidence

    by Sina Salem Ahim, Maryam Kazemi, Melika Boroomand-Saboor, Zeinab Zamanpour, Hamideh Rahbarinezhad, Tahereh Mahmoodvand, Sara Ghaseminejad Kermani, Sadaf Rassouli, Zahra Hamidi Madani

    Introduction: Preeclampsia (PE) is a leading cause of maternal and perinatal morbidity worldwide, and early identification of at-risk pregnancies remains a clinical priority. This systematic review synthesizes evidence from the past decade to evaluate the diagnostic performance and clinical utility of uterine artery Doppler (UAD) sonography in predicting and guiding management of PE. Materials and Methods: We systematically searched PubMed, Embase, Scopus, Web of Science, Cochrane Library, and Google Scholar for English-language original studies published between 2016 and 2025 that evaluated UAD parameters for predicting PE. Two reviewers independently extracted data on study design, gestational timing, Doppler findings, and diagnostic accuracy using a standardized form. Results: In this review of 18 observational and cohort studies published over the past decade, UAD sonography demonstrated moderate to high diagnostic accuracy for predicting PE, with parameters such as pulsatility index (PI), resistive index (RI), and the presence of a diastolic notch, alone or in combination, yielding sensitivities ranging from ~60% to 91% and specificities up to 99%. First-trimester assessments showed particular promise, especially when Doppler indices were combined with biochemical markers, and second-trimester measurements maintained predictive value for both early- and late-onset disease. Conclusion: These findings pose UAD sonography as a noninvasive, cost-effective tool for early risk stratification of PE and support its incorporation into routine antenatal screening. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251173030 and the Research Registry (UIN: reviewregistry2054) websites.

  • Open Access

    Updated insights into cancer risk and pathogenesis in systemic lupus erythematosus; a nephrology viewpoint on recent evidence

    by Sina Salem Ahim, Paradise Fatehi Shalamzari, Faezeh Nesaei, Faezeh Khajeh, Seyed Amir Sheikholeslami, Sara Teihou Jorshari, Seyed Amir Banikarim, Naeem Nikpour

    Patients with systemic lupus erythematosus (SLE) exhibit a distinct cancer risk profile characterized by increased susceptibility to hematologic malignancies such as non-Hodgkin lymphoma (NHL), as well as certain solid tumors like lung, thyroid, and hepatobiliary cancers. Conversely, they also demonstrate a reduced risk for some cancers including breast, melanoma, and prostate cancer. This unique pattern is influenced by a combination of disease-related immune dysregulation and treatment-related factors. Additionally, immunosuppressive therapy administered in SLE management, including agents like cyclophosphamide, is known to contribute to an elevated risk of malignancies such as cervical dysplasia and certain hematologic cancers. However, specific immunosuppressants like calcineurin inhibitors have shown no significant increase in cancer incidence in some cohorts, suggesting that cancer risk is multifactorial and may depend on the type and duration of immunosuppression. However, in SLE patients, screening practices for cancers like cervical cancer are suboptimal despite their increased risk. However, some studies have found lower cervical cancer screening rates in women with SLE compared to control subjects, which influenced by factors like age, income, and comorbidities. Improved screening uptake is crucial for early cancer detection and better outcomes in this vulnerable population. Moreover, lupus nephritis enhances cancer risk and progression through complex interplay of chronic inflammation, immune dysregulation, treatment effects, and molecular pathway alterations. Inflammation-induced oxidative stress and impaired autophagy, combined with immunosuppressive therapies, provide a background for malignant transformation and decreased tumor immune surveillance.

  • Association between cardiometabolic index and kidney stones; a systematic review and meta-analysis

    by Sina Salem Ahim

    Introduction: T Kidney stone is a common urological disease, and high values of cardiometabolic index (CMI) are primarily linked with metabolic disorders, including obesity, insulin resistance and metabolic syndrome, which are associated with the formation of kidney stones (nephrolithiasis). Accordingly, our study aimed to investigate the relationship between high CMI values and the risk of kidney stones. Materials and Methods: Databases such as Web of Science, Cochrane, Scopus, PubMed, Embase, and Google Scholar Search Engine were conducted for articles published until August 27, 2025. Data were analyzed using STATA 14. Tests with P values<0.05 were considered statistically significant. Results: Results revealed that high CMI levels increased the risk of kidney stones (OR=1.39, 95% CI: 1.31, 1.47). As high CMI values in the second one-third (OR=1.38, 95% CI: 1.25, 1.52), third one-third (OR=1.35, 95% CI: 1.22, 1.49), second quartile (OR=1.31, 95% CI: 1.11, 1.56), third quartile (OR=1.45, 95% CI: 1.23, 1.71), and fourth quartile (OR=1.57, 95% CI: 1.33, 1.85) increased the risk of kidney stones. Additionally, high CMI levels increased the risk of kidney stones in men (OR=1.28, 95% CI: 1.16, 1.42), women (OR=1.28, 95% CI: 1.18, 1.39), patients with BMIs 25-30 (OR=1.21, 95% CI: 1.08, 1.35), patients with BMIs ≥ 30 (OR=1.25, 95% CI: 1.12, 1.39), patients younger than 60 (OR=1.24, 95% CI: 1.13, 1.37), patients older than 60 (OR=1.36, 95% CI: 1.26, 1.48), and diabetic individuals (OR=1.52, 95% CI: 1.36, 1.70). Conclusion: High CMI levels increased the risk of kidney stone formation by 39%. The risk was similar in men and women; however, the risk of kidney stones increased with the patients’ age. Furthermore, obese individuals were at a higher risk compared with those who were overweight. Registration: This study has been compiled in accordance with the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD420251141496) and Research Registry (UIN: reviewregistry2044) websites.

  • When tumors break bones; emerging paradigms in the pathogenesis and prevention of oncologic skeletal fractures

    by Sina Salem Ahim, Z. Ganjali, R. Hassanshahi, Z. Karimi, M. Forghan, A. Alilou, A. Norouzbeygi, H.E. Jelodar

    Oncologic skeletal fractures or pathologic fractures resulting from tumor-induced bone destruction represent a devastating complication of both primary bone cancers and metastatic disease, profoundly impairing patient quality of life and survival. Traditionally viewed as mechanical failures secondary to osteolytic or osteoblastic lesions, emerging paradigms now recognize these fractures as the culmination of complex, dynamic interactions between tumor cells and the bone microenvironment. Recent advances highlight the role of tumorsecreted factors, which dysregulate normal bone remodeling by takeover of osteoclast and osteoblast activity, leading to structural weakening long before radiographic changes appear. Moreover, the concept of the vicious cycle between tumor growth and bone resorption has been expanded to include immune modulation, angiogenesis, and neural signaling within the skeletal niche. Novel imaging modalities and biomechanical modeling now enable earlier detection of at-risk bone, while biomarkers offer promise for risk stratification. Therapeutically, beyond bisphosphonates and denosumab, emerging strategies target specific molecular pathways like TGF-β, Wnt, CXCR4 to disrupt tumor-bone crosstalk and preserve skeletal integrity. Additionally, prophylactic stabilization guided by fracture risk assessment tools is increasingly personalized. Meanwhile, prevention, rather than reaction, is becoming the cornerstone of management, emphasizing collaboration among oncologists, orthopedic surgeons, radiologists, and bone biologists.